<DOC>
	<DOCNO>NCT02273596</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety WTX101 administer 24 week newly diagnose Wilson Disease ( WD ) patient age 18 old Nonceruloplasmin-bound copper ( NCC ) level within normal reference range time enrollment . Subjects Wilson Disease receive either prior Wilson Disease treatment , treat include 24 month prior study enrollment chelation therapy ( e.g . trientine , penicillamine ) , zinc therapy combination therapy eligible participate , inclusion exclusion criterion meet . The purpose 12 month Extension Phase evaluate durability , establish long-term safety efficacy WTX101 .</brief_summary>
	<brief_title>Efficacy Safety Study WTX101 Adult Wilson Disease Patients</brief_title>
	<detailed_description />
	<mesh_term>Hepatolenticular Degeneration</mesh_term>
	<criteria>Willing able give inform consent participation study . Male female patient , age 18 year old sign ICF . Able understand willing comply study procedure , restriction requirement , judge Investigator . Established diagnosis Wilson Disease LeipzigScore ≥ 4 ( Ferenci et al 2003 ) document test outlined 2012 EASL WD Clinical Practice Guidelines . NCC level within normal reference range ( 0.8 2.3 μM ) . Willing undergo 48 hour washout current Wilson Disease treatment Treatment great 24 month Wilson Disease chelation therapy ( i.e . penicillamine , trientine hydrochloride ) zinc therapy . Decompensated hepatic cirrhosis . Model EndStage Liver Disease ( MELD ) score &gt; 11 . Modified Nazer score &gt; 6 ( Dhawan et al . Liver Transplant 2005 ) . GI bleed within past 6 month . ALT &gt; 5x upper limit normal ( ULN ) . Marked neurological disease require either nasogastric ( NG ) feed intensive inpatient medical care . Severe anaemia haemoglobin &lt; 9 mg/dL .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>